The end of drug shortages begins with data transparency
For more than 15 years, shortages of critical drugs — from oncology treatments to emergency room and surgical suite essentials — have burdened healthcare systems and compromised patient car
Newsletters and Deep Dive digital magazine
For more than 15 years, shortages of critical drugs — from oncology treatments to emergency room and surgical suite essentials — have burdened healthcare systems and compromised patient car
The industry is showing its teeth, as companies have started slashing positions.
Selective serotonin reuptake inhibitors (SSRIs) are the first-line drug therapy of choice for most people suffering from depression but often fail to work effectively.
Our round-up of recent biotech financings is headed by a sizeable $200 million third round for Zenas BioPharma, with Cellectis, Reunion Neuroscience, Karius, Context Thera
The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to paus
Editor's Picks
Newsletters and Deep Dive
digital magazine